This article is part of the supplement: The Scientific Basis of Rheumatology
Therapy of systemic lupus erythematosus: a look into the future
-
Correspondence: Josef S Smolen smj@2me.khl.magwien.gv.at
Department of Rheumatology, Internal Medicine III, Vienna General Hospital, University of Vienna, and 2nd Department of Medicine, Lainz Hospital, Vienna, Austria
Arthritis Res 2002, 4(Suppl 3):S25-S30 doi:10.1186/ar579
Published: 9 May 2002Abstract
This manuscript is dedicated to Professor Tiny Maini in admiration of his grand mind and great work, in thankful appreciation of the numerous hours of our scientific debates, discussions on the future of rheumatology, and great personal enjoyment over the past 15 years, and with sincere gratitude for his support, guidance, and friendship over so many years.
The prognosis for patients with systemic lupus erythematosus has greatly improved over the past two decades. However, therapies that are more effective and that have fewer sequelae are needed to rescue patients from organ failure and further reduce mortality. Research under way, including that into induction of tolerance to self-antigens, prevention of the consequences of pathogenic autoantibody production, interference with the cytokine network and signal transduction, the identification and treatment of any infectious triggers, and stem cell therapy, offers hope of improved remedies or even of cure. Given the fact that a number of biological therapies for rheumatologic disease are already in use or are in the development stage, such progress may come soon.